Interview 2 May 2017 Video Interview: Meet the Inventor of the Surgical Super-glue At our second meetup in Basel last week, Philip had the chance to talk to Maria Pereira, one of Forbes’ 30 under 30 and the scientific inventor of the technology behind Gecko Biomedical. Apart from telling us about Gecko’s progress and future plans, Maria talked about her time in Boston and why she ended up […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 French HIV Cure Reduces Viral Reservoirs for the First Time Ever Abivax has announced results from a Phase IIa trial that reveal the first proof in human of viral load reduction of hidden HIV reservoirs. Abivax is developing a functional HIV cure that, unlike current antiretroviral therapy (ART), could completely eliminate the virus and prevent it from coming back when the treatment is stopped. Results from a Phase IIa […] May 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin With Berlin’s plethora of life science research and academia, opportunities abound for biotech entrepreneurs. Here’s how the city bridges the gap between science and business! So much research, so many opportunities for academics and entrepreneurs. Berlin boasts 35 large research institutions focused on life sciences, and around 130 hospitals — including Europe’s largest and most […] May 2, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 1 May 2017 This Founder is using Synbio to Revolutionize Genetic Medicine Oxford Genetics founder and CEO Ryan Cawood told me about his company’s improvements to DNA design for better biologicals. Last month at Synbiobeta, I caught up with Ryan Cawood, who created one of the most successful synthetic biology companies around, Oxford Genetics. “Our direction actually took off from this conference,” he told me. “We saw […] May 1, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2017 These Bioartists Turn Cell-to-Cell Communication in your Body into Sound Thought Collider and David Young have developed an installation that transforms the faint communication signals between your skin cells into sounds. Artist duo Thought Collider is comprised of Mike Thompson, from the UK, and Susana Cámara Leret, from Spain. Based in Amsterdam and London, they experiment with the living nature of our bodies and microorganisms. Their […] April 29, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2017 The Tires of the Future will be made with… Dandelions? Continental, famous producer of tires, is creating a research facility in Germany to investigate the use of rubber extracted from dandelions. An eventual switch to the material would mean less environmental impact, and maybe even better tires. The “green pet project” of Continental, a giant automotive manufacturer with almost €40Bn yearly revenues, consists of replacing conventional natural […] April 28, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Apr 2017 This Dutch Biotech Could Boost Gene Editing of Primary Cells Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in 2015 based on a cutting-edge intracellular delivery technology developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. Mission: NTrans is developing the iTOP technology for its use in research and as a therapeutical platform for the delivery of bioactive molecules into […] April 28, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2017 Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […] April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Inside Labiotech 27 Apr 2017 Wait but why is Labiotech.eu based in Berlin? After “How do you make money,” that’s the question I am asked most. Here’s the answer for all the curious people out there! As you might already know, Labiotech.eu started in France. I was studying bioengineering with Joachim (the first guy I talked to on the first day of the first year!) at Sup’Biotech, and […] April 27, 2017 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community Take note, Spain is becoming a new hotspot for biotech in Europe. More than €400M of venture capital, counting recent fundraising and anticipated closings, is forecasted to be available this year to fund the creation and growth of start-ups in the life sciences sector. Behind the growing interest among investors are novel opportunities with breakthrough potential […] April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2017 BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […] April 26, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email